OpGen, Inc., has opened a CLIA certified Laboratory and has launched a clinical services laboratory with a focus on developing a best-in-class portfolio of genetic tests and analysis services for the surveillance and identification of healthcare associated infections (HAIs) and human pathogens.OpGen´s clinical services laboratory utilizes next generation DNA and genetic analysis technologies that include multiplex real-time PCR, Whole Genome Mapping and next generation sequencing. This comprehensive suite of capabilities enables OpGen to provide low cost, genetic testing for screening, surveillance, diagnosis, gene content and epidemiologic analysis of infectious diseases. OpGen offers Whole Genome Mapping genetic analysis of HAIs, as well as sequence analysis of C. difficile on a worldwide basis. Additionally, the company will offer real-time PCR screening and surveillance of MRSA and complete C. difficile hyper-virulence diagnostic testing services in the mid-Atlantic region. The company is actively developing tests for a broad array of gram-negative and gram-positive multi-drug resistant organisms.
Please note : Any products described on this page are
for Research Use Only and not intended for clinical diagnostic procedures unless otherwise stated.
